CMC Readiness for an IND or IMPD: What Regulators Expect at Phase 1

The short answer: At Phase 1 a regulator wants enough chemistry, manufacturing and controls (CMC) information to be confident the investigational product is identified, pure enough, stable enough and made consistently enough to be safe in the volunteers who will take it. That is a lower bar than a marketing application, but a precise one: a described and controlled manufacturing process, phase-appropriate specifications and analytical methods, an impurity assessment that covers safety, stability data that supports the trial, and sites working to GMP. The gaps that cause clinical holds and information requests are rarely exotic; they are missing impurity qualification, methods that cannot be shown to work, stability that does not cover the trial, and inconsistency between the sections. An independent CMC readiness review before submission is designed to find exactly those.

The two filings differ in form but not in substance. In the US the CMC content of an Investigational New Drug application follows the FDA's guidance on the content and format of INDs for Phase 1 studies and, for manufacturing controls, the 2008 guidance on CGMP for Phase 1 Investigational Drugs. In the EU the Investigational Medicinal Product Dossier (IMPD) is submitted under the Clinical Trials Regulation and follows the EMA guideline on the requirements for the chemical and pharmaceutical quality documentation of investigational medicinal products (and its biological counterpart). Both are organised like the CTD Module 3: drug substance (S) and drug product (P).

What "phase-appropriate" means

Phase-appropriate does not mean optional. It means the depth of each section matches what is known and what is at stake. At Phase 1 regulators expect:

• a manufacturing process that is described and controlled, not yet validated;
• specifications that are justified by the batches made so far, with acceptance criteria that may be wider than the eventual commercial ones but are set, not deferred;
• analytical methods that are shown to be suitable for their purpose, with full ICH Q2(R2) validation expected later;
• an impurity and degradant assessment that is complete on safety, because volunteers are exposed now;
• stability data that covers the planned duration of the trial, with a commitment to continue on stability and to act on out-of-trend results.

What can wait: process validation, full method validation, long-term stability to a commercial shelf life, and the commercial control strategy. What cannot wait: anything that bears on the safety of the material being dosed.

Drug substance (Module 3.2.S): the readiness checklist

1. Nomenclature, structure and general properties (S.1), including stereochemistry and salt or solvate form, consistent across every section.
2. Manufacturer (S.2.1): name and address of each site, including contract sites, and evidence each operates under GMP appropriate to the phase.
3. Description of the manufacturing process (S.2.2): flow diagram, steps, quantities, operating conditions, and a clear statement of the starting materials with the rationale ICH Q11 asks for.
4. Control of materials (S.2.3): specifications for starting materials, reagents and solvents; any material of animal or human origin flagged with its safety documentation.
5. Controls of critical steps and intermediates (S.2.4), as far as they are known.
6. Characterisation (S.3): structure elucidation and, critically, the impurity profile: organic impurities and their identification thresholds, residual solvents against ICH Q3C, elemental impurities against ICH Q3D, and an assessment of potentially mutagenic impurities under ICH M7, including nitrosamine risk where the chemistry allows it.
7. Specification (S.4.1) and justification (S.4.5): tests, methods and acceptance criteria tied to the batches actually made, with the batch analyses (S.4.4) for the lots used in toxicology and those planned for the clinic.
8. Analytical procedures and their suitability (S.4.2, S.4.3): what has been done to show each method works, and the plan to validate.
9. Reference standards (S.5): source, qualification and how they are maintained.
10. Container closure (S.6) and stability (S.7): data on representative batches under relevant conditions, a retest period or use period that covers the trial, and the ongoing programme.

Drug product (Module 3.2.P): the readiness checklist

1. Description and composition (P.1): every component with its function and quantity; placebo and comparator described where used.
2. Pharmaceutical development (P.2): a short, honest account of why the formulation and process were chosen and what is known about the critical quality attributes; ICH Q8(R2) thinking at Phase 1 depth.
3. Manufacture (P.3): sites, batch formula, process description and in-process controls; for sterile products, the sterilisation or aseptic approach with reference to EU GMP Annex 1 and the FDA's aseptic processing guidance.
4. Control of excipients (P.4): compendial status or a specification; novel excipients need their own safety data.
5. Control of drug product (P.5): specification, methods and suitability, batch analyses, and characterisation of impurities and degradants with the same safety-first logic as the drug substance.
6. Reference standards (P.6), container closure (P.7) with compatibility and extractables considerations where the product is parenteral.
7. Stability (P.8): data supporting the trial duration and the in-use or dilution conditions the protocol describes, and the commitment to continue.

Manufacturing controls: GMP at Phase 1

Phase 1 material is made to GMP, but the FDA's 2008 guidance recognises that the controls can be scaled to the stage: documented procedures, qualified equipment, controlled materials, trained people, records and a quality unit, without the full commercial quality system. In the EU, investigational medicinal products are released by a Qualified Person, and the IMPD names the sites with their manufacturing authorisation. Whichever framework applies, the dossier and the site's actual practice have to match; a described control that the site does not perform is a finding waiting to happen. The GMP certificate of a contract site proves an inspection took place, not that your product's controls are in place there, so the quality agreement has to carry them.

Where Phase 1 filings get stuck

• Impurities not qualified for the exposure. An impurity above its identification or qualification threshold with no toxicology coverage is the classic safety-driven hold.
• Methods asserted, not shown. "Validated in-house" without system suitability, specificity and a stability-indicating demonstration invites an information request.
• Stability that runs out before the trial does. A 3-month data set for a 9-month study, with no interim plan, is a gap regulators notice immediately.
• Inconsistency between sections. A specification in S.4.1 that does not match the batch data in S.4.4; a batch size in P.3 that does not match the stability batches in P.8; a site in S.2.1 that is not the one on the certificates.
• Starting-material designation too late in the synthesis, leaving GMP steps undocumented.
• Sterility assurance described vaguely for an injectable: the filtration, container closure integrity and aseptic process controls have to be specific.

A one-week readiness exercise

Before submission, give the dossier to someone who did not write it and have them check five things: that every number in the specifications is backed by a batch result; that every method has a suitability demonstration; that the impurity assessment names its thresholds and covers mutagenic risk; that stability covers the trial plus margin; and that the sites named match the certificates. That exercise takes days and prevents the 30-day clock or the Clinical Trials Regulation timetable from becoming months. If no one on the team can do it independently, PharmaTek's CMC readiness review does it for a fixed fee, with a traffic-light report and a prioritised gap list.

Frequently asked questions

How much CMC data is needed for a Phase 1 IND? Enough to show the investigational product is identified, pure enough, stable enough and made consistently enough to be safe in the planned study: a described and controlled process, phase-appropriate specifications tied to real batch data, methods shown to be suitable, a complete impurity and degradant safety assessment, stability covering the trial, and GMP-appropriate manufacturing. Validation of the process and full method validation come later.

What is the difference between an IND CMC section and an IMPD? Both follow the Module 3 structure (drug substance S and drug product P) and ask for the same substance: process, controls, specifications, impurities, stability and GMP sites. The IND is reviewed by the FDA with a 30-day clock before the study may proceed; the IMPD is part of a Clinical Trials Regulation application in the EU, with release of investigational product by a Qualified Person. Content written to one can usually be adapted to the other with attention to regional specifics such as excipient status and sterility assurance expectations.

What CMC problems cause a clinical hold? Issues that bear on the safety of the dosed material: unqualified impurities or degradants, including potentially mutagenic impurities, inadequate sterility assurance for an injectable, methods that cannot be shown to detect what matters, insufficient stability to cover the trial, or an inability to assure consistent manufacture. Inconsistencies between dossier sections often trigger information requests that delay the start even without a formal hold.

Does Phase 1 clinical trial material need to be made under GMP? Yes. In the US the FDA's 2008 guidance on CGMP for Phase 1 investigational drugs allows controls scaled to the stage, but documented procedures, qualified equipment, controlled materials, trained staff, records and a quality function are still expected. In the EU investigational medicinal products are manufactured under a manufacturing authorisation and certified by a Qualified Person.

When should a small company get an independent CMC review? Four to eight weeks before the planned submission, once the batch data and stability data exist but while there is still time to run a confirmatory test or fix an inconsistency. Earlier, at the point of choosing a CDMO or planning a tech transfer, a review of the plan rather than the dossier prevents the gaps from arising at all.

---

Filing in the next two quarters? The CMC and tech-transfer readiness review gives you a fixed-fee, vendor-neutral read of the package before the regulator does. Selecting the manufacturer first? Start with the CDMO selection checklist and screen candidates in the directory.